AavantiBio logo
Startup

AavantiBio

See AavantiBio's full profile

BOOK A DEMO
Headquarters

United States

Founded Year

2020

Total Funding

$107.0M

Employees

11 - 50

Status

Active


About AavantiBio

AavantiBio is a pre-clinical biopharmaceutical company committed to developing and commercializing novel gene transfer and gene editing therapies for the treatment of rare and ultra-rare genetic diseases.

Headquarters

United States


General Information on AavantiBio

Brand name AavantiBio
Company name AavantiBio Inc.
Website https://www.aavantibio.com/
Founded year 2020
Employees 11 - 50
Founding team

Barry Byrne

BO CUMBO

Contact [email protected]

Find startup solutions in your specific business context

The INNOSPOT Startup Discovery platform helps you to find the right startup solutions by leveraging the world's most powerful Startup Search Engine analyzing millions of data points.
BOOK A DEMO

Recent News and Activity about AavantiBio

Yahoo! Finance 02.12.2022
Solid Biosciences Announces Stockholder Approval of Acquisition of AavantiBio

Solid Biosciences Inc. · 5 min read In this article: SLDB - Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases - CHARLESTOWN, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the results of the special meeting of the ...

AavantiBio news
TheFly 02.12.2022
Solid Biosciences stockholders approve acquisition of AavantiBio

Sign up for our 14-day free trial to read this story.

AavantiBio news
Swissquote (Switzerland) (German) 01.12.2022
BRIEF-Solid Biosciences Announces Stockholder Approval Of Acquisition Of Aavantibio

Dec 1- Solid Biosciences Inc:* SOLID BIOSCIENCES ANNOUNCES STOCKHOLDER APPROVAL OF ACQUISITION OF AAVANTIBIO

Pharmaphorum (UK) 04.10.2022
Solid Biosciences acquires AavantiBio, conducts $75 million private placement

The life sciences company Solid Biosciences is merging with the privately-held gene therapy company AavantiBio in a deal which is expected to result in a combined sum of $215 million in cash and investments – projected to be enough for funding into 2025. AavantiBio, a precision genetic medicine company that was bankrolled by Solid’s rival Sarepta back in 2020, focuses on neuromuscular and cardiac rare diseases. Its key assets include product ...

AavantiBio news
Htv10.tv 05.01.2022
AavantiBio to Present at the 40th Annual J.P. Morgan Healthcare Conference

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference. The live presentation and Q&A session, which will occur virtually, will take place on January 12, 2022 at approximately 10:30am ET. About AavantiBio, Inc. AavantiBio is a gene therapy company backed by ...

AavantiBio news
FOX 40 WICZ TV (NY) 16.11.2021
AavantiBio Further Enhances Leadership Team with Appointment of Jenny Marlowe, Ph.D. as Chief Scientific Officer

“We are delighted to have Jenny join the AavantiBio team and expand our scientific and early-stage development capabilities. She brings a wealth of leadership and expertise in research, toxicology, and investigation of gene therapies and shares our commitment to serving patients with rare genetic diseases,” said Bo Cumbo, President and Chief Executive Officer of AavantiBio. “Jenny’s deep experience in the development of cell and gene therapies ...

AavantiBio news
FirstWord Pharma 16.11.2021
AavantiBio Appoints Jenny Marlowe as Chief Scientific Officer

Dr. Marlowe brings to AavantiBio nearly 15 years of experience in the biopharmaceutical industry, including extensive experience in molecular biology, drug safety, and nonclinical and translational development. She joins from Bluebird Bio Inc. (NASDAQ: BLUE) where she previously served as Vice President of Preclinical & Translational Development, with responsibilities for preclinical development and translational biomarker strategies for the ...

Fierce Biotech 16.11.2021
AavantiBio snags another bluebird bio VP with gene therapy chops as sixth executive hire this year

AavantiBio has poached another bluebird bio leader to bring its lead gene therapy program into clinical trials. Bluebird's vice president of preclinical and translational development is leaving to become chief scientific officer of the one-year-old biotech. Jenny Marlowe, Ph.D., departs bluebird two months after the company asked the FDA to approve its gene therapy betibeglogene autotemcel (approved in the E.U. as Zynteglo) for a severe genetic ...

AavantiBio news
Financialbuzz.com 13.10.2021
AavantiBio Furthers Strategic Partnership with University of Florida to Research and Develop Next Generation Gene Therapy Capsids

the University of Florida to research and develop next generation gene therapy capsids with the goal of creating safer, more effective, and tissue specific gene therapies. The expansion of this partnership will enable AavantiBio to further build out its platform focused on advancing innovative gene therapies in areas of significant unmet medical need. The Adeno-associated virus (AAV) is the “delivery vehicle” for gene therapy, but the AAV's ...

The Register-Herald 12.10.2021
AavantiBio Furthers Strategic Partnership with University of Florida to Research and Develop Next Generation Gene Therapy Capsids Oct 12, 2021 Oct 12, 2021 Updated 13 min ago

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced it is partnering with the University of Florida to research and develop next generation gene therapy capsids with the goal of creating safer, more effective, and tissue specific gene therapies. The expansion of this partnership will enable AavantiBio to further build out its platform focused on advancing innovative gene ...

AavantiBio news